1. Home
  2. DAL vs NTRA Comparison

DAL vs NTRA Comparison

Compare DAL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delta Air Lines Inc.

DAL

Delta Air Lines Inc.

HOLD

Current Price

$70.03

Market Cap

38.2B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$226.17

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAL
NTRA
Founded
1924
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.2B
32.9B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
DAL
NTRA
Price
$70.03
$226.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
15
Target Price
$79.06
$249.53
AVG Volume (30 Days)
8.3M
1.1M
Earning Date
01-13-2026
02-26-2026
Dividend Yield
1.09%
N/A
EPS Growth
43.72
N/A
EPS
7.66
N/A
Revenue
$63,364,000,000.00
$2,116,676,000.00
Revenue This Year
N/A
$33.77
Revenue Next Year
$5.64
$16.92
P/E Ratio
$9.02
N/A
Revenue Growth
2.79
38.17
52 Week Low
$34.74
$125.38
52 Week High
$73.16
$256.36

Technical Indicators

Market Signals
Indicator
DAL
NTRA
Relative Strength Index (RSI) 56.17 40.55
Support Level $64.47 $229.14
Resistance Level $68.30 $235.62
Average True Range (ATR) 2.15 7.88
MACD -0.12 -1.80
Stochastic Oscillator 81.12 11.44

Price Performance

Historical Comparison
DAL
NTRA

About DAL Delta Air Lines Inc.

Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: